John G Ullman & Associates Inc. Has $4.90 Million Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

John G Ullman & Associates Inc. reduced its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 11.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,750 shares of the specialty pharmaceutical company's stock after selling 5,344 shares during the quarter. John G Ullman & Associates Inc. owned 0.07% of Jazz Pharmaceuticals worth $4,895,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Pacer Advisors Inc. raised its holdings in shares of Jazz Pharmaceuticals by 5.5% during the fourth quarter. Pacer Advisors Inc. now owns 2,214,480 shares of the specialty pharmaceutical company's stock valued at $272,713,000 after acquiring an additional 115,102 shares during the period. Franklin Resources Inc. raised its holdings in shares of Jazz Pharmaceuticals by 4.6% during the third quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company's stock valued at $124,208,000 after acquiring an additional 48,708 shares during the period. Thompson Siegel & Walmsley LLC raised its holdings in shares of Jazz Pharmaceuticals by 8.3% during the third quarter. Thompson Siegel & Walmsley LLC now owns 781,215 shares of the specialty pharmaceutical company's stock valued at $87,035,000 after acquiring an additional 59,685 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in shares of Jazz Pharmaceuticals by 8.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 531,710 shares of the specialty pharmaceutical company's stock valued at $59,238,000 after acquiring an additional 42,587 shares during the period. Finally, Bank of New York Mellon Corp raised its holdings in shares of Jazz Pharmaceuticals by 5.4% during the fourth quarter. Bank of New York Mellon Corp now owns 477,751 shares of the specialty pharmaceutical company's stock valued at $58,835,000 after acquiring an additional 24,481 shares during the period. 89.14% of the stock is currently owned by institutional investors.

Remove Ads

Jazz Pharmaceuticals Stock Up 0.9 %

JAZZ stock traded up $1.28 during trading hours on Wednesday, hitting $140.23. The company's stock had a trading volume of 1,088,753 shares, compared to its average volume of 741,445. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The company has a market capitalization of $8.52 billion, a PE ratio of 19.75, a price-to-earnings-growth ratio of 1.04 and a beta of 0.56. Jazz Pharmaceuticals plc has a 12 month low of $99.06 and a 12 month high of $148.06. The stock has a 50 day moving average price of $127.64 and a two-hundred day moving average price of $119.71.

Analysts Set New Price Targets

A number of research firms have recently issued reports on JAZZ. Barclays restated an "overweight" rating and set a $200.00 price target (up previously from $190.00) on shares of Jazz Pharmaceuticals in a report on Thursday, February 27th. HC Wainwright reaffirmed a "buy" rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. Cantor Fitzgerald downgraded shares of Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and boosted their price objective for the company from $140.00 to $150.00 in a research report on Wednesday, February 26th. Morgan Stanley raised shares of Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and boosted their price objective for the company from $140.00 to $175.00 in a research report on Thursday, December 12th. Finally, TD Cowen lowered their price objective on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a "buy" rating on the stock in a research report on Thursday, November 7th. Two analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $182.47.

Insiders Place Their Bets

In related news, CAO Patricia Carr sold 4,813 shares of the company's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $144.42, for a total transaction of $695,093.46. Following the completion of the sale, the chief accounting officer now directly owns 8,237 shares of the company's stock, valued at approximately $1,189,587.54. This represents a 36.88 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Bruce C. Cozadd sold 6,500 shares of the company's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $144.25, for a total transaction of $937,625.00. Following the sale, the chief executive officer now directly owns 464,058 shares of the company's stock, valued at approximately $66,940,366.50. This represents a 1.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 18,113 shares of company stock valued at $2,551,834 over the last ninety days. Corporate insiders own 4.20% of the company's stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.